[ANMCO/SIC Consensus statement on pulmonary arterial hypertension]

G Ital Cardio

20 June Jun 2024 one month ago
  • Agostoni P.

Pulmonary hypertension (PH) is a frequent pathological condition worldwide, mainly secondary to cardiovascular and respiratory diseases, with a poor prognosis. Pulmonary arterial hypertension (PAH) is a rare form that affects the arterial pulmonary vasculature. PH and PAH are characterized by non-specific symptoms and a progressive increase of pulmonary vascular resistance that results in progressive, sometimes irreversible, right ventricular dysfunction. In recent years, a growing medical and social commitment on this disease allowed more accurate diagnosis in shorter times. However, the gap between guidelines and clinical practice remains a challenge for all medical doctors involved in the disease management. Considering the needs to share and describe diagnostic and therapeutic pathways, to measure the results obtained and to address the economical and organizational problems of this disease, all involved figures should collaborate to improve its prognostic impact and health expenses. In this consensus document, the PH experts of the Italian Association of Hospital Cardiologists (ANMCO) together with those of the Italian Society of Cardiology (SIC), address 1) definition, classification and unmet needs of PH and PAH; 2) classification and characteristics of centers involved in the diagnosis and treatment of the disease; 3) proposal of organization of a diagnostic-therapeutic pathway, based on robust and recent scientific evidence.

Reference: [ANMCO/SIC Consensus statement on pulmonary arterial hypertension].
Vatrano M, Manzi G, Picariello C, D'Alto M, Enea I, Ghio S, Caravita S, Argiento P, Garascia A, Vitulo P, Gabrielli D, Agostoni P, Corda M, Sinagra G, Grimaldi M, Scelsi L, Badagliacca R, D'Agostino C, Perrone Filardi P, Colivicchi F, Indolfi C, Roncon L, Galiè N, Oliva F, Vizza CD. G Ital Cardiol (Rome). 2024 Mar;25(3):192-201.

Go to PubMed